Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Consulting agrmnt CC transcript Director departure Inv. presentation
|
Orexigen Therapeutics, Inc. (OREXQ)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/04/2012 |
PRN
| Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences |
07/09/2012 |
PRN
| Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference |
06/06/2012 |
PRN
| Orexigen® Therapeutics and Sharecare® Announce Partnership for WeightMate™, a Comprehensive Weight Management Program |
05/31/2012 |
PRN
| Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference |
04/27/2012 |
PRN
| Lota S. Zoth Joins Orexigen Therapeutics Board of Directors |
02/06/2012 |
PRN
| Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave® Outcomes Trial |
12/22/2011 |
PRN
| Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock |
12/14/2011 |
PRN
| Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock |
10/03/2011 |
PRN
| Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society |
06/01/2011 |
PRN
| Orexigen® Therapeutics Schedules June 3, 2011 Webcast and Conference Call to Provide a Regulatory Update on Contrave® NDA |
05/02/2011 |
PRN
| Orexigen® Therapeutics Schedules May 9, 2011 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2011 |
04/26/2011 |
PRN
| Orexigen® Therapeutics Announces Upcoming Data Presentations at The American College of Obstetricians and Gynecologists Annual Clinical Meeting |
04/04/2011 |
PRN
| Orexigen?? Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring |
03/29/2011 |
PRN
| Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting |
03/10/2011 |
PRN
| Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results |
03/10/2011 |
PRN
| Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results |
03/03/2011 |
PRN
| Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010 |
02/17/2011 |
PRN
| Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer |
02/09/2011 |
PRN
| Orexigen® Therapeutics Announces Corporate Realignment |
07/29/2010 |
PRN
| Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet |
06/26/2010 |
PRN
| Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression |
06/25/2010 |
PRN
| Orexigen(R) Therapeutics Presents New Data Showing Contrave(R) Significantly Lowers Weight, Improves Blood Glucose Control in Obese Patients With Type 2 Diabetes |
06/25/2010 |
PRN
| Orexigen(R) Therapeutics Presents New Data Showing Contrave(R) Significantly Lowers Weight, Improves Blood Glucose Control in Obese Patients With Type 2 Diabetes |
06/21/2010 |
PRN
| Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association Annual Scientific Meeting |
|
|